Skip to main content

Thomas James E's Form 4/A amendment

Amended

Clarus Therapeutics Holdings, Inc. (CRXT) · filed Apr 25, 2022

Accession no.
0001062993-22-010736
Filed
Apr 25, 2022, 5:17 PM ET
Trade date
Apr 20, 2022
Filing delay
5 days
Rule 10b5-1 plan
Not on the form (before 2023)
Original filed
Apr 21, 2022

This filing lists 6 non-derivative transactions. Open-market sales total $9.49M. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Thomas James ECIK 000120478910% Owner
TMP Associates LPCIK 000122628010% Owner
Thomas McNerney & Partners LPCIK 000123129110% Owner
Thomas, McNerney & Partners, LLCCIK 000133519610% Owner
TMP Nominee, LLCCIK 000133520010% Owner
Thomas, McNerney & Partners II L.P.CIK 000136957410% Owner
TMP Associates II LPCIK 000138303510% Owner
TMP Nominee II, LLCCIK 000143605410% Owner
Thomas, McNerney & Partners II, LLCCIK 000150593010% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 20, 2022Common StockSSaleDisposed−1,663,126$2.53F1−$4,207,708.78773,599Indirect
Apr 20, 2022Common StockSSaleDisposed−2,061,685$2.53F1−$5,216,063.05958,989Indirect
Apr 20, 2022Common StockSSaleDisposed−5,722$2.53F1−$14,476.662,661Indirect
Apr 20, 2022Common StockSSaleDisposed−13,630$2.53F1−$34,483.96,340Indirect
Apr 20, 2022Common StockSSaleDisposed−1,164$2.53F1−$2,944.92542Indirect
Apr 20, 2022Common StockSSaleDisposed−7,585$2.53F1−$19,190.053,528Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The prices reported in this column are weighted average prices at a range of prices between $2.20 and $3.03. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges of the prices reported.

Referenced by the price of 6 transactions in Table I.

F2

The reported securities are held directly by Thomas, McNerney & Partners, L.P. ("TMP"). Thomas, McNerney & Partners, LLC ("TMP LLC") is the general partner of TMP and TMPA and has shared voting and dispositive power of the securities held by TMP and TMPA, but disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. James E. Thomas is the sole manager of TMP LLC. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such person's or entity's pecuniary interest in such securities.

F3

The reported securities are held directly by Thomas, McNerney & Partners II, L.P. ("TMP II"). Thomas, McNerney & Partners II, LLC ("TMP II LLC") is the general partner of TMP II and TMPA II and has shared voting and dispositive power of the securities held by TMP II and TMPA II, but disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. James E. Thomas is the sole manager of TMP II LLC. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such person's or entity's pecuniary interest in such securities.

F4

The reported securities are held directly by TMP Nominee, LLC ("TMPN"). James E. Thomas and Peter McNerney are the managers of TMPN and TMPN II and, as a result, may be deemed to have voting and dispositive power over the shares held by TMPN and TMPN II, respectively, provided that they are obligated to exercise such power in the same manner as TMP LLC and TMP II LLC vote and dispose of the securities of the Issuer over which TMP LLC and TMP II LLC exercise voting and dispositive power, respectively. James E. Thomas is the sole manager of TMP LLC and TMP II LLC. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such person's or entity's pecuniary interest in such securities.

F5

The reported securities are held directly by TMP Nominee II, LLC ("TMPN II"). James E. Thomas and Peter McNerney are the managers of TMPN and TMPN II and, as a result, may be deemed to have voting and dispositive power over the shares held by TMPN and TMPN II, respectively, provided that they are obligated to exercise such power in the same manner as TMP LLC and TMP II LLC vote and dispose of the securities of the Issuer over which TMP LLC and TMP II LLC exercise voting and dispositive power, respectively. James E. Thomas is the sole manager of TMP LLC and TMP II LLC. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such person's or entity's pecuniary interest in such securities.

F6

The reported securities are held directly by TMP Associates, L.P. ("TMPA"). TMP LLC is the general partner of TMP and TMPA and has shared voting and dispositive power of the securities held by TMP and TMPA, but disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. James E. Thomas is the sole manager of TMP LLC. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such person's or entity's pecuniary interest in such securities.

F7

The reported securities are held directly by TMP Associates II, L.P. ("TMPA II"). TMP II LLC is the general partner of TMP II and TMPA II and has shared voting and dispositive power of the securities held by TMP II and TMPA II, but disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. James E. Thomas is the sole manager of TMP II LLC. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of such person's or entity's pecuniary interest in such securities.

Remarks

This Form 4 was previously filed under the incorrect CIK (for Clarus Therapeutics Inc.) and is being refiled under the correct CIK.

Read the full filing on SEC EDGAR (opens in a new tab)